Customization: | Available |
---|---|
CAS No.: | 231277-92-2 |
Formula: | C29h26clfn4o4s |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Products Name : |
Lapatinib |
CAS No.: | 231277-92-2 |
Synonyms | lapatinib;n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-;Lapatinib(TINIBS);Lapatinib Base N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine;GW2016 LAPATINIB;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;N-{3-chloro-4-[(3-fluorobenzyl)oxyl]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine |
Appearance: |
White crystalline powder |
Assay: | 99%min |
Molecular formula | C29H26ClFN4O4S |
Molecular weight | 581.0575432 |
EINECS Number | 1806241-263-5 |
Melting point | 96-97°C |
Boiling point | 750.7±60.0 °C |
Density | 1.381±0.06 g/cm3 |
Storage temp. | Store at RT |
Description:
Lapatinib, a new member of the 4-anilinoquinazoline class of RTK inhibitors (RTKIs), was launched as an oral treatment for breast cancer. Lapatinib has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated in combination for treating patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy
Application:
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.